Volume 82 | ESPE2014 | Next issue

ESPE 2014

Dublin, Ireland
18 Sep 2014 - 20 Sep 2014

Card image cap
Dublin, Ireland; 18-20 September 2014. Further information

Poster Category 2

Growth Hormone (1)

Perceptions and Expectations of Patients and their Families for the Effects of GH Treatment
Department of Endocrinology-Growth and Development, ‘P & A Kyriakou’ Children’s Hospital, Athens, Greece
hrp0082p2-d2-422
Normal Onset of Clinical Puberty for Age in GH-Treated Children with Noonan Syndrome or Turner Syndrome: Data from the NordiNet® IOS and ANSWER® Program
aThomas Jefferson University, Philadelphia, Pennsylvania, USA; bHans Christian Andersen Children’s Hospital, Odense University Hospital, Odense, Denmark; cPenn State College of Medicine, The Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA; dNovo Nordisk, Inc., Princeton, New Jersey, USA; eGlobal Development, Novo Nordisk A/S, Søborg, Denmark; fDepartment of Pediatric Endocrinology, UMC University Children’s Hospital, Ljubljana, Slovenia
hrp0082p2-d2-423
What Dose of hGH is Adequate as a Substitution Therapy in GH Deficient Children?
Division of Endocrinology, Metabolism and Diabetes, 1st Department of Pediatrics, Medical School, National and Kapodistrian University of Athens, Athens, Greece
hrp0082p2-d2-424
Electronic Devices and Single-Dose Dispensing Systems GH are the Most Efficient and Less Loss of Drug
aChildren’s Endocrinology Section, Pediatric Service, Vitoria/Basque Country, Spain; bPharmacy Service, University Hospital of Alava, Itoria/Basque Country, Spain
hrp0082p2-d2-425
Effects and Safety of Recombinant Human GH in GH Deficient Children with Rathke Cyst
Department of Pediatrics, Sun Yat-sen Memorial Hospital, Guangzhou, China
hrp0082p2-d2-427
What Should be the Diagnosis and Management of Short Children with IGF1 Deficiency, Responding to GH Administration Despite Normal GH Secretion?
aDepartment of Endocrinology and Metabolic Diseases, Polish Mother’s Memorial Hospital, Research Institute, Lodz, Poland; bDepartment of Endocrinology and Metabolic Diseases, Medical University of Lodz, Lodz, Poland; cDepartment of Pediatric Endocrinology, Medical University of Lodz, Lodz, Poland
hrp0082p2-d2-429
A Reappraisal of the Cut-Off Limits of the Peak GH Response to Stimulation Tests for the Diagnosis of GH Deficiency in Children and Adolescents
aServizio di Endocrinologia Pediatrica, Ospedale Microcitemico, Cagliari, Italy; bOspedale Generale Regionale, Bolzano, Italy; cUniversità di Genova/IRCCS Giannina, Genova, Italy; dUniversità di Bologna, Ospedale S. Orsola-Malpighi, Bologna, Italy; eUnità Operativa di Endocrinologia, Ospedale Pediatrico Bambin Gesu’, Roma, Italy
hrp0082p2-d2-430
Growth Hormone Treatment in Children with SGA During a 5-Year Period, Assessment of Auxological Development and Insulin Resistance
aHospital Materno-Infantil de Málaga, Málaga, Spain; bHospital Virgen de la Macarena, Sevilla, Spain; cHospital Sagrado Corazón, Barcelona, Spain; dHospital Arnau de Vilanova, Lleida, Spain; eHospital Virgen del Mar, Cádiz, Spain; fMerck S.L., Madrid, Spain
hrp0082p2-d2-432
Metabolic Assessment in Children with GH Deficiency Before, During, and After Human GH Replacement Therapy
Department of Medical and Surgical Sciences of the Mother, Children and Adults, University of Modena and Reggio Emilia, Modena, Italy
hrp0082p2-d2-434